Herombopag for Chemotherapy-induced Thrombocytopenia
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of Herombopag to treat chemotherapy-induced
thrombocytopenia in Solid Tumors
Phase:
Phase 2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital
Collaborators:
Henan Cancer Hospital The Second Affiliated Hospital of Kunming Medical University Tianjin Medical University Cancer Institute and Hospital Tianjin Medical University Second Hospital Tianjin People's Hospital Tianjin Third Central Hospital